Previous Article | Next Article 
J Virol, January 1998, p. 158-163, Vol. 72, No. 1
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus Lacking Glycoprotein gp42 Can
Bind to B Cells but Is Not Able To Infect
Xi
Wang and
Lindsey M.
Hutt-Fletcher*
School of Biological Sciences, University of
Missouri
Kansas City, Kansas City, Missouri 64110
Received 4 August 1997/Accepted 25 September 1997
 |
ABSTRACT |
The Epstein-Barr virus gH-gL complex includes a third glycoprotein,
gp42, which is the product of the BZLF2 open reading frame (ORF). gp42
has been implicated as critical to infection of the B lymphocyte by
virtue of its interaction with HLA class II on the B-cell surface. A
neutralizing antibody that reacts with gp42 inhibits virus-cell fusion
and blocks binding of gp42 to HLA class II; antibody to HLA class II
can inhibit infection, and B cells that lack HLA class II can only be
infected if HLA class II expression is restored. To confirm whether
gp42 is an essential component of the virion, we derived a recombinant
virus with a selectable marker inserted into the BZLF2 ORF to interrupt
expression of the protein. A complex of gH and gL was expressed by the
recombinant virus in the absence of gp42. Recombinant virus egressed
from the cell normally and could bind to receptor-positive cells. It had, however, lost the ability to infect or transform B lymphocytes. Treatment with polyethylene glycol restored the infectivity of recombinant virus, confirming that gp42 is essential for penetration of
the B-cell membrane.
 |
INTRODUCTION |
Entry of enveloped viruses into
mammalian cells requires that the virion envelope fuse with the cell
membrane after attachment to the cell surface. Herpesviruses require
the functions of multiple protein species to mediate this event, and in
keeping with the common origin and diverse habitats of these viruses,
some of the proteins involved in penetration appear to be conserved
throughout the family and some appear to be restricted to individual
members or more closely related members with similar tropism. The two glycoproteins gH and gL fall into the first category of conserved proteins. Glycoprotein gH has been implicated as a major player in
virus-cell fusion in many herpesviruses (8, 10, 11, 22, 28, 32,
34), and gL is an essential partner which is required for folding
and transport of gH out of the endoplasmic reticulum (6, 19, 21,
27, 28, 35, 38, 45). The gH and gL homologs of Epstein-Barr virus
(EBV) are gp85, the product of the BXLF2 open reading frame (ORF)
(13, 31), and gp25, the product of the BKRF2 ORF
(45), and these homologs appear to behave much as their
counterparts in other herpesviruses do (45). However, a
third glycoprotein, gp42, associates with the EBV gH-gL complex and
falls into the second category of proteins, those with a more
restricted distribution.
Glycoprotein gp42 is the product of the BZLF2 ORF (26), and
although there may be a functionally similar protein in cytomegalovirus (18, 24), it is not predicted to have a homolog in other
human herpesviruses. It does, however, have a homolog in ORF51 of
equine herpes virus 2 (43). Both EBV and equine herpes virus
2 infect B lymphocytes (1), and several lines of evidence
suggest that, at least in the case of EBV, gp42 is critical to the
infection of this cell type. A monoclonal antibody (MAb) called F-2-1
that reacts with gp42 has no affect on EBV attachment to its receptor, complement receptor type 2 (CR2) (CD21), but inhibits fusion of the
virus with the B-cell membrane and neutralizes infection
(29). Glycoprotein gp42 interacts with the
1
domain of the HLA class II protein HLA-DR (39), and MAb
F-2-1 interferes with this interaction (25). Like F-2-1, a
MAb to HLA-DR or a soluble form of gp42 can block B-cell
transformation, and B-cell lines which lack expression of HLA class II
are not susceptible to superinfection with EBV unless expression of HLA
class II is restored (25). Collectively these observations
suggest that gp42, probably by virtue of its interaction with HLA class
II, is essential to infection of the B lymphocyte. To answer directly
the question of whether gp42 is an indispensable glycoprotein, we
derived a virus that could be definitively shown to lack expression of
the molecule and examined its ability to infect normal resting B
lymphocytes. We report here that virus with expression of gp42 blocked
can exit cells normally and can bind to receptor-positive target cells.
However, it is unable to penetrate into cells and initiate infection.
 |
MATERIALS AND METHODS |
Cells.
Akata, a Burkitt lymphoma-derived cell line that
carries and can be induced to make EBV (41) (a gift of John
Sixbey, St. Jude Children's Research Hospital, Memphis, Tenn.);
EBV-negative Akata cells (a gift of Jeffrey Sample, St. Jude
Children's Research Hospital); Raji (33), an EBV
genome-positive, nonproducing human B-cell line that expresses CR2; and
P3HR1-C15 (15), an EBV-positive human B-cell line that does
not express CR2 (a gift of George Miller, Yale University, New Haven,
Conn.), were grown in RPMI 1640 (Sigma Chemical Co., St. Louis, Mo.)
supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL
Life Technologies, Grand Island, N.Y.). Human leukocytes were obtained
from heparinized adult peripheral blood or from cord blood by flotation
on lymphocyte separation medium and were depleted of T cells by a
double cycle of rosetting with sheep erythrocytes as previously
described (26).
Virus.
EBV was obtained from Akata cells which were
resuspended at a concentration of 4 × 106 per ml and
induced with 100 µg of anti-human immunoglobulin G per ml for 6 days.
Virus to be used for extraction of DNA was harvested by high-speed
centrifugation from spent culture medium which had been clarified by
centrifugation at 4,000 × g for 10 min and was
purified twice by sedimentation in dextran (30). Virus to be
used for cell infection was harvested from clarified culture medium
that had been passed through a 0.8-µm-pore-size filter.
Preparation and transfection of constructs used for homologous
recombination.
Dextran-purified virus harvested from the spent
medium of 8 × 109 Akata cells was digested with
proteinase K, and virion DNA was purified three times by centrifugation
in cesium chloride. DNA that sedimented at a density of 1.718 g of
cesium per ml was digested with EcoRI. The 22.6-kb EBV
EcoRI C fragment, which begins at bp 95238 of the B95-8
sequence and ends at approximately bp 117800 and includes the BZLF2 ORF
(42), was cloned into the multiple cloning site of
pBluescript II (Stratagene, La Jolla, Calif.). A 5.7-kb
SpeI/SalI fragment, corresponding to bp 99537 to
105296 of the B95-8 sequence (3), was subcloned into the
same vector, producing a fragment that had a unique HpaI
site in the BZLF2 ORF (bp 102116 to 101448) 182 bp from the initiation
codon. A 1.5-kb XmnI/HincII fragment, containing the
neomycin resistance (Neor) gene under control of the simian
virus 40 promoter, was digested from pcDNA3 (Invitrogen, San Diego,
Calif.), blunt ended, and cloned into this HpaI site at bp
101934. The SpeI/SalI fragment, now 7.2 kb by
virtue of the insertion of the Neor gene, was purified and
used to transfect Akata cells with DEAE-dextran (2). Twenty
million cells were incubated with 10 µg of DNA and 0.4 mg of dextran
for 90 min at 37°C, washed, resuspended in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum (Gibco) at a
concentration of 2 × 106 cells per ml, and cultured
for 2 days. Cells were then plated at 104 per well in
96-well tissue culture plates in medium containing 700 µg of G418
(Gibco) per ml and fed weekly with fresh drug-containing medium.
Resistant clones began to emerge after approximately 3 weeks.
Derivation of cells containing only recombinant episomes.
Drug-resistant Akata cells that contained wild-type episomes and
episomes that had undergone homologous recombination with the
Neor gene-containing fragment were induced with
anti-immunoglobulin. After 6 days, 1 ml of spent culture medium,
diluted 1/15, was used to infect 5 × 106 EBV-negative
Akata cells. After 2 more days of culture, the cells were plated in
96-well plates at 104 per well in medium containing 700 µg of G418. Resistant clones began to emerge after approximately 3 weeks.
Antibodies.
MAbs F-2-1 (40), which reacts with
gp42 (26); E1D1 (31), which reacts with the EBV
gH-gL complex (26); and 72A1, which reacts with gp350
(17), were obtained from spent culture medium of hybridoma
cells grown in RPMI 1640 supplemented with 20% heat-inactivated fetal
bovine serum. Two anti-peptide antibodies were made to synthetic peptides corresponding to residues 125 to 137 of gpL (45)
and to residues 219 to 232 of gp150, respectively (23). All
antibodies were purified by chromatography on protein A (Sigma) coupled
to Affigel-15 (Bio-Rad, Richmond, Calif.).
Radiolabeling and immunoprecipitation.
EBV proteins were
labeled biosynthetically with [3H]glucosamine (20 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) for 20 h at
6 h after induction with anti-human immunoglobulin G as previously described (45). Labeled cells were solubilized in
radioimmunoprecipitation buffer (50 mM Tris-HCl [pH 7.2], 0.15 M
NaCl, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS],
0.1 mM phenylmethylsulfonyl fluoride, and 100 U of aprotinin per ml)
and immunoprecipitated with antibody and protein A-Sepharose CL4B
(Sigma). Immunoprecipitated proteins were washed, dissociated by
boiling in sample buffer containing 2-mercaptoethanol, and analyzed by
SDS-polyacrylamide gel electrophoresis in acrylamide cross-linked with
0.28% N,N'-diallyltartardiamide, followed by
fluorography.
Slot blot assays.
The amount of EBV DNA in cells or virion
particles was measured by hybridization with the BamHI W
fragment of EBV DNA labeled with 32P by means of a
random-primed DNA labeling kit (Boehringer Mannheim, Indianapolis,
Ind.). Serial dilutions of cells (8 × 104 to 2.5 × 103) in phosphate-buffered saline were applied to a
charged nylon membrane (Magnacharge; Micron Separations Inc.,
Westborough, Mass.) with a slot blot filtration manifold. Membranes
were treated as previously described (20) except that DNA
was cross-linked by UV irradiation rather than by baking the membrane.
Samples (150 µl) of culture supernatant containing virus were
filtered through a 0.8-µm-pore-size filter to remove cells and
digested for 10 min at room temperature with DNase I. Five microliters
of 0.5 M EDTA was added, and virus particles were sedimented for 1 h at 16,000 × g. Sedimented virus was digested
overnight at 56°C with proteinase K (12 mg per ml in 0.2 M EDTA), and
serial dilutions were made in phosphate-buffered saline. The DNA in
each sample was denatured by the addition of 1/10 volume of 5N NaOH,
neutralized with 2 M ammonium acetate, applied to a nylon membrane, and
cross-linked by UV irradiation. Hybridizations were carried out as
described previously (20) and quantified by scanning with a
Molecular Dynamics Storm PhosphorImager.
Southern blotting.
Cells were digested overnight at 56°C
with proteinase K (1 mg per ml in 100 mM NaCl, 10 mM Tris-HCl [pH
8.0], 25 mM EDTA, and 0.5% SDS), and DNA was purified by
phenol-chloroform extraction and ethanol precipitation. Purified DNA
was digested overnight with EcoRI and HindIII
and separated by agarose gel electrophoresis in 0.7% agarose.
Separated DNA was transferred to a nylon membrane (Magnacharge) by
capillary action, cross-linked, and hybridized either with the 5.7-kb
SpeI/SalI fragment corresponding to bp 99537 to
105296 of the B95-8 sequence or with the
XmnI/HincII fragment of pcDNA3 containing the
Neor gene. Both probes were labeled with 32P.
Virus binding assays.
Akata cells (140 million) containing
wild-type or recombinant virus were induced with goat anti-human
immunoglobulin in 8 ml of medium. Four hours later 500 µCi of
[3H]thymidine (20 to 30 Ci per mmol; Amersham) was added,
and 30 min later the volume of medium was increased to 80 ml. After 3 days of incubation virus was harvested from the culture supernatant by
centrifugation and resuspended in 800 µl of fresh medium. EBV receptor-positive Raji and EBV receptor-negative P3HR1-C15 cells were
fixed in ice-cold 0.1% paraformaldehyde, and the ability of the
radiolabeled virus to bind to the cells in the presence or absence of
antibody 72A1 to gp350 was determined as previously described
(29).
Assays for infection of B cells.
Five million
T-cell-depleted peripheral blood leukocytes were incubated at 37°C
with 300 µl of dilutions of filtered culture supernatant from induced
Akata cells. After 2 h, the volume was brought to 5 ml with medium
containing serum and the cells were reincubated. Five hundred thousand
EBV-negative Akata cells were incubated with 150 µl of virus for
2 h at 37°C, after which the volume was brought to 3 ml and the
cells were reincubated. Five days later both leukocytes and Akata cells
were harvested and analyzed by Western blotting for expression of EBNA
1. In addition, 600,000 T-cell-depleted peripheral blood leukocytes
were incubated for 2 h at 37°C with 240 µl of virus, plated in
quintuplicate at 105 cells per well in 96-well tissue
culture plates, and reincubated for 4 weeks, at which time the wells
were examined for the presence of transforming foci.
Western blotting.
Cells were lysed in immunoprecipitation
buffer, electrophoresed in polyacrylamide, and then electrically
transferred onto nitrocellulose membranes (0.45-µm pore size;
Schleicher and Schuell, Inc., Keene, N.H.) at 20 mA for 18 h. The
transferred sheets were treated for at least 3 h with blocking
buffer (10 mM Tris-HCl [pH 7.2], 0.15 M NaCl, 5% skim milk, 0.05%
sodium azide) and reacted for at least 3 h with blocking buffer
containing a 1/500 dilution of EBNA 1-positive human serum. They were
then washed five times with wash buffer (10 mM Tris-HCl [pH 7.2],
0.15% NaCl, 0.3% Tween 20) for 10 min each time followed by an
overnight wash. The washed sheets were reacted with alkaline
phosphatase-conjugated goat anti-human antibodies (Hyclone) for 3 h, and the bound anti-human antibodies were detected by reacting with
substrate 5-bromo-4-chloro-3-indolylphosphate and Nitro Blue
Tetrazolium (Sigma).
Polyethylene glycol-mediated infection.
Samples of 5 × 106 T-cell-depleted peripheral blood leukocytes were
incubated for 1 h on ice with recombinant virus or growth medium.
Cells were washed once and gently resuspended in 1 ml of 35%
polyethylene glycol 1500 (Boehringer Mannheim) or serum-free medium for
5 min. Ten milliliters of medium was added, and cells were centrifuged
at 400 × g, resuspended in fresh growth medium, and
incubated for 14 days before being harvested and subjected to Western
blot analysis. In some experiments cells were fed weekly and kept until
outgrowth of cell lines occurred.
 |
RESULTS |
Generation of recombinant EBV with a selectable marker in the BZLF2
ORF.
Several different strategies have been used to derive EBV
with expression of individual proteins blocked. However, the Akata strain of EBV can be induced synchronously with anti-human
immunoglobulin to make virus (41), and it is easier to label
less abundant proteins like gp42 in Akata cells, which produce
relatively high numbers of viruses, than in other EBV-producing cell
lines. We therefore derived Akata virus with expression of gp42 blocked by transfection of Akata cells with a 7.2-kb fragment of Akata DNA that
encompassed the BZLF2 ORF and contained the Neor gene 182 bp from its 5' end. Cells in which recombination had occurred were
obtained by selection in the presence of G418.
A total of 253 drug-resistant clones were derived from 2,976 wells of
transfected cells that had been plated in the drug at a concentration
of 10,000 per well. To determine whether illegitimate or homologous
recombination had occurred in each clone, DNA was extracted, digested
with EcoRI and HindIII, and screened with a
5.7-kb SpeI/SalI fragment that corresponded to
the fragment used for transfection except that it lacked the insertion
of the Neor gene. This probe was predicted to visualize
three fragments of 7,652, 3,285, and 189 bp in cells harboring
wild-type EBV episomes and an additional fragment of 9,156 bp in cells
harboring both wild-type and recombinant episomes (Fig.
1). Sixteen of the 253 drug-resistant
clones had restriction patterns that were indicative of homologous
recombination in one or more episomes (data not shown).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Diagram of the positions of the EcoRI and
HindIII sites, numbered according to the B95-8 sequence,
surrounding the SpeI/SalI fragment targeted for
homologous recombination. The boxes above the line indicate the
position of the SpeI/SalI fragment used as a
probe and the insertion of the Neor gene at bp 101934. (B)
Sizes of fragments expected from DNA from cells harboring wild-type
episomes, a mixture of wild-type and recombinant episomes, or pure
recombinant episomes after digestion with EcoRI and
HindIII and probing with the 5.7-kb
SpeI/SalI fragment.
|
|
Akata cells which have lost the EBV episome are available
(
36) and can be used to propagate recombinant EBV
(
37). To derive
cells that contained only recombinant
episomes, cells from each
of two positive clones with the appropriate
restriction patterns
were induced with anti-human immunoglobulin, and
virus harvested
from the spent culture medium was used to infect
EBV-negative
Akata cells. Twelve drug-resistant clones that grew out
after
infection with virus from each parental clone were tested for
the
ease with which they could be induced to make virus and for
the
presence of recombinant but not wild-type episomes. None of
the clones
derived from one parent could be readily induced to
express virus, as
judged by indirect immunofluorescence with a
MAb called 72A1, which
reacts with the abundant late protein gp350.
Although they contained
episomes with the pattern expected of
recombinant virus on Southern
blotting, they were not studied
further. The clones derived from the
other parent varied in inducibility,
with between 7 and 30% of the
cells expressing gp350. All contained
only recombinant episomes, as
judged by Southern blotting and
probing with the
SpeI/
SalI fragment (Fig.
2). Probing with the
XmnI/
HincII fragment of pcDNA3 containing the
Neo
r gene confirmed that the resistance gene was inserted
at only
one site in the extracted DNA.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 2.
Southern blot analysis of DNA extracted from Akata cells
harboring wild-type episomes (Wt), a parental clone of Akata cells
harboring a mixture of wild-type and recombinant episomes (Wt + Rc), and a clone derived from the parental clone which contains only
recombinant episomes (Rc). DNA was digested with EcoRI and
HindIII, and the two identical halves of the membrane
were cut apart and probed either with the
SpeI/SalI fragment of EBV or the
XmnI/HincII fragment containing the
Neor gene as indicated. Sizes in kilobases are indicated by
the arrows.
|
|
Lack of expression of gp42 in cells harboring only recombinant
episomes.
To determine whether expression of gp42 had been lost as
a result of the insertion of the Neor gene into the BZLF2
ORF, cells were induced with anti-human immunoglobulin, labeled with
[3H]glucosamine, and immunoprecipitated with antibodies
to EBV glycoproteins. Glycoproteins gp350 (running at the top of the
gel) and gp150 were immunoprecipitated from Akata cells harboring
either wild-type or recombinant episomes (Fig.
3). The gH-gL-gp42 complex could be
immunoprecipitated either by antibody F-2-1 or by an anti-peptide antibody to gp25 from cells harboring wild-type episomes. In contrast, however, no proteins were immunoprecipitated by antibody F-2-1 from
cells harboring recombinant episomes and antibody to gL
immunoprecipitated a complex that included only gH and gL. This
indicated that the gH-gL complex was still intact but that it lacked
its third member, gp42. To confirm that the gH-gL complex was
transported to the cell surface normally, Akata cells harboring
recombinant episomes were induced with anti-human immunoglobulin and 2 days later cells were briefly fixed in ice-cold 0.1% paraformaldehyde
and incubated with MAb E1D1, which reacts with a complex of gH and gL.
MAb E1D1, visualized by rabbit anti-mouse serum conjugated to
fluorescein, stained the surfaces of cells carrying recombinant
episomes as well as it did cells harboring wild-type virus (Fig.
4). Indirect immunofluorescence staining
with MAb E1D1 of virus bound to Raji cells also indicated that the
gH-gL complex was present in virions that lacked gp42 (data not shown).

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 3.
Electrophoretic analysis of proteins immunoprecipitated
by MAb 72A1 to gp350, MAb F-2-1 to gp42, or rabbit anti-peptide
antibodies to gp150 or gp25 from Akata cells harboring wild-type or
recombinant episomes. The cells were induced with anti-human
immunoglobulin and labeled with [3H]glucosamine. The
arrows and numbers at the right indicate the masses of the
immunoprecipitated proteins in kilodaltons.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Indirect immunofluorescence staining of Akata cells
harboring only recombinant episomes (A) or wild-type episomes (B).
Cells were induced with anti-human immunoglobulin for 48 h, fixed
in 0.1% paraformaldehyde, and reacted with MAb E1D1 to the gH-gL
complex followed by anti-mouse immunoglobulin conjugated to
fluorescein.
|
|
Recombinant virus can exit cells.
Glycoproteins are involved
in both entry and egress of viruses. To determine whether exit of virus
lacking gp42 occurred normally, a slot blot assay was used to assess
the total amount of virus DNA associated with induced cells and that of
the DNase-resistant virion DNA that could be pelleted from spent
culture medium after it had been filtered through a 0.8-µm-pore-size
filter to remove the cells. The values obtained for each were then
compared for wild-type and recombinant virus. The ratio of virus DNA in
cells containing wild-type virus versus that in cells containing
recombinant virus was approximately 1.3, and the ratio of released and
encapsidated virus DNA in wild-type virus versus that in recombinant
virus was approximately 1.1 (Table 1).
This indicated that failure to express gp42 had no significant effect
on release of virus from the cell.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Quantitation by slot blot hybridization of the relative
amounts of EBV DNA in induced cells harboring wild-type or recombinant
episomes and in virus pelleted from spent culture media
|
|
Recombinant virus can bind to B cells.
To determine whether
virus derived from recombinant cells was able to bind to
receptor-positive cells, virus was labeled intrinsically with
[3H]thymidine and its ability to bind to
receptor-negative P3HR1-C15 cells or receptor-positive Raji cells in
the presence or absence of antibody to gp350 was evaluated. The amount
of labeled virus that bound to receptor-positive Raji cells was
slightly higher for recombinant than for wild-type virus in this
experiment (Table 2). However, in both
cases the amount of acid-precipitable radioactivity bound to the cells
could be reduced by antibody to an amount similar to that associated
with receptor-negative cells. This indicated that the initial binding
of virus to cells via an interaction between CR2 and gp350 was not
affected by the lack of expression of gp42.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Binding of [3H]thymidine-labeled
recombinant or wild-type virus to receptor-positive and
-negative cells
|
|
Recombinant virus cannot infect B cells.
The ability of
recombinant virus to infect B lymphocytes was then evaluated in terms
of its ability to induce EBNA 1 in resting B cells or EBV-negative
Akata cells and in terms of its ability to transform resting B cells.
Slot blot analyses had indicated that the culture supernatant from
Akata cells making wild-type virus contained 1.3 times as much virus as
did supernatant from cells making recombinant virus. However, even
undiluted recombinant virus was unable to induce EBNA 1 in peripheral
blood leukocytes (Fig. 5A) or in
EBV-negative Akata cells (Fig. 5B), whereas dilutions of 1/8 of
wild-type virus induced EBNA 1 in both cell types. Wild-type virus at a
dilution of 1/200 was able to transform peripheral blood leukocytes,
whereas recombinant virus was unable to produce transformation foci at
any dilution from 1/5 to 1/200 (Table 3).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 5.
Induction of EBNA 1 in T-cell-depleted peripheral blood
leukocytes (A) or EBV-negative Akata cells (B) mock infected (0) or
infected 5 days previously with wild-type (Wt) or recombinant (Rc)
viruses at the dilutions indicated. Western blots were reacted with
human serum containing antibody to EBNA 1 and with goat anti-human
immunoglobulin conjugated to alkaline phosphatase.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Comparison of the ability of wild-type and recombinant
virus to transform T-cell-depleted peripheral blood leukocytes
|
|
Polyethylene glycol restores the infectivity of recombinant
virus.
Previous work has implicated gp42 in fusion of virus with
the cell membrane (29). Since recombinant virus was able to
bind to cells, we determined whether treatment of cells and bound virus with polyethylene glycol would restore the ability of recombinant virus
to transform cells. Fourteen days after infection cells were harvested
and examined for the presence of EBNA by Western blotting. Cells that
had been infected with virus in the presence of polyethylene glycol,
but not cells infected with recombinant virus alone, expressed EBNA
(Fig. 6A). A B-cell line was also derived
by the same protocol and is shown on the same Western blot. DNA from
this line was extracted to confirm that it had been immortalized by
recombinant virus rather than by any endogenous virus harbored by the
donor of the cells. Southern blotting confirmed that recombinant virus
carrying the Neor gene was the virus present in the
immortalized line (Fig. 6B).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 6.
Infection and transformation of T-cell-depleted
peripheral blood leukocytes with recombinant virus in the presence of
polyethylene glycol. (A) Western blot analysis of Akata cells
containing wild-type virus (Wt); a B-cell line derived from peripheral
blood leukocytes by infection with recombinant virus in the presence of
polyethylene glycol (PBL/Rc); or freshly isolated leukocytes harvested
14 days after mock infection (Mock), treatment with polyethylene glycol
alone (PEG), infection with recombinant virus (Rc), or infection with
recombinant virus in the presence of polyethylene glycol (PEG+Rc).
Western blots were reacted with human serum containing antibody to EBNA
1 and with goat anti-human immunoglobulin conjugated to alkaline
phosphatase. (B) Southern blot analysis of DNA extracted from Akata
cells containing wild-type virus (Wt), a parental clone containing a
mixture of recombinant and wild-type virus (Wt+Rc), Akata cells
containing pure recombinant virus (Rc), and the B-cell line derived
from peripheral blood leukocytes by infection with recombinant virus in
the presence of polyethylene glycol (PBL/RC). DNA was digested with
EcoRI and HindIII. The blot (left) was probed
with the SpeI/SalI fragment of EBV, and then
(right) stripped and reprobed with the 1.5-kb
XmnI/SalI fragment containing the
Neor gene. Sizes in kilobases are indicated by the
arrows.
|
|
 |
DISCUSSION |
Indirect evidence has implicated the EBV glycoprotein gp42 as
being essential to infection of B lymphocytes, and the work reported
here confirms that B cells cannot be infected with virus that fails to
express it. In addition, however, the development of strategies for
isolating recombinant EBV genomes in virus strains that can be induced
to make relatively large amounts of virus (37) has allowed
us to evaluate the relative importance of the protein to several
independent steps in the virus life cycle. As predicted by experiments
with individually expressed recombinant proteins (25), gp42
is not required for the formation of an SDS-stable gH-gL complex that
is transported to the cell surface. It also has no significant effect
on the egress of virus, and its absence does not alter the specificity
of virus binding to CR2-positive cells. Defects in virus that lacks
gp42 appear to be limited to postbinding events.
The virus that fails to express gp42 may not be a true null mutant. The
insertion of the Neor gene 182 bp from the initiation codon
of the BZLF2 ORF that encodes gp42 might permit synthesis of a
truncated 61-amino-acid protein. Unfortunately, we currently have no
reagents that might identify such a species. Such a protein, if made,
would include the putative signal sequence of gp42, and it is possible
that the 61 amino acids still include the domain responsible for the
interaction between gp42 and gH and gL. A truncated protein would,
however, retain none of the four potential N-linked glycosylation sites and none of the 11 cysteine residues of the native molecule. As demonstrated experimentally (see above), it would also no longer express the epitope recognized by MAb F-2-1, which is identical with,
or very close to, the site of interaction with MHC class II. It would
therefore not be expected to be functional.
Most of the studies done to date suggest that gp42 is involved in the
fusion of virus and cell membranes, and the ability of polyethylene
glycol to restore infectivity of virus that fails to express the
protein is consistent with this hypothesis. Polyethylene glycol has
been used both to enhance virus binding and to facilitate fusion of
membranes (7, 12, 14, 16). There is, however, no reason to
suppose that the recombinant virus made here is in any way deficient in
binding. Unlike the primary interactions of the alphaherpesviruses,
like herpes simplex virus, with cell surfaces, which are of low
affinity, the gp350-CR2 interaction is a high-affinity reaction.
Although gp42 binds to MHC class II on the cell surface, neither
antibodies to gp42 nor antibodies to MHC class II that block this
binding have any effect on the ability of virus to bind to cells via
CR2; rather, in the case of antibody F-2-1, which blocks the
interaction of gp42 and MHC class II, virus-cell fusion is inhibited
(29).
Glycoprotein gp42 is a type II membrane protein with an uncleaved
signal peptide (25, 26, 39). Its amino acid sequence includes no other domain that is predicted to be hydrophobic, and it
seems unlikely that the molecule is directly involved in the fusion
process. Of the three proteins that make up the EBV gH-gL complex, gH,
as the most hydrophobic of the three molecules, is perhaps the most
likely to play that role and has in fact been implicated as doing so in
other herpesviruses (4, 5, 8-11). It is clear, however,
that even if gH is a prime mover in EBV fusion with the B lymphocyte
surface, the protein is not functional in the absence of gp42. We have
speculated (25) that the interaction of gp42 with MHC class
II might be required simply to bring virus closer to the cell membrane
than does the initial interaction between gp350 and CR2 or that perhaps
signaling via MHC class II is important in some way for the induction
of changes in cell surface behavior. The association of gp42 with gH
and gL as an integral part of the complex rather than as a separate
entity in the membrane would suggest that, whatever its role is, it is one that is closely linked, either spatially or temporally, to those of
its partners. The relatively low number of receptors for EBV, estimated
to be approximately 30,000 per cell (44) even on the
high-level-expressing Raji line, does not lend itself well to
definitive electron microscopic analysis of the sequential events in
EBV entry. However, the blocking of virus lacking gp42 at the cell
surface opens up new possibilities in this regard. Complementation of
recombinant virus with gp42 which contains defined mutations should
also provide new insight into the complexity of the role that the
molecule plays in B-cell infection.
 |
ACKNOWLEDGMENT |
This research was supported by Public Health Service grant
AI20662 from the National Institute of Allergy and Infectious Diseases.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: School of
Biological Sciences, University of Missouri
Kansas City, 5007 Rockhill
Rd., Kansas City, MO 64110. Phone: (816) 235-2575. Fax: (816) 235-5158. E-mail: huttfletcher{at}cctr.umkc.edu.
 |
REFERENCES |
| 1.
|
Agius, C. T., and M. J. Studdert.
1994.
Equine herpesvirus 2 and 5: comparisons with other members of the subfamily gammaherpesvirinae.
Adv. Virus Res.
44:357-379[Medline].
|
| 2.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
1997.
.
Current protocols in molecular biology.
John Wiley and Sons, Inc., New York, N.Y.
|
| 3.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
G. Hatfull,
S. C. Satchwell,
C. Seguin,
P. S. Tuffnell, and B. G. Barrell.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature (London)
310:207-211[Medline].
|
| 4.
|
Davis-Poynter, N.,
S. Bell,
T. Minson, and H. Browne.
1994.
Analysis of the contributions of herpes simplex virus type 1 membrane proteins to the induction of cell-cell fusion.
J. Virol.
68:7586-7590[Abstract/Free Full Text].
|
| 5.
|
Desai, P. J.,
P. A. Schaffer, and A. C. Minson.
1988.
Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity.
J. Gen. Virol.
69:1147-1156[Abstract/Free Full Text].
|
| 6.
|
Duus, K. M.,
C. Hatfield, and C. Grose.
1995.
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy.
Virology
210:429-440[Medline].
|
| 7.
|
Fehler, F.,
J. M. Herrmann,
A. Saalmüller,
T. C. Mettenleiter, and G. M. Keil.
1992.
Glycoprotein IV of bovine herpesvirus 1-expressing cell line complements and rescues a conditionally lethal viral mutant.
J. Virol.
66:831-839[Abstract/Free Full Text].
|
| 8.
|
Forghani, B.,
L. Ni, and C. Grose.
1994.
Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex.
Virology
199:458-462[Medline].
|
| 9.
|
Forrester, A.,
H. Farrell,
G. Wilkinson,
J. Kaye,
N. Davis-Poynter, and T. Minson.
1992.
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted.
J. Virol.
66:341-348[Abstract/Free Full Text].
|
| 10.
|
Fuller, A. O.,
R. E. Santos, and P. G. Spear.
1989.
Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.
J. Virol.
63:3435-3443[Abstract/Free Full Text].
|
| 11.
|
Gompels, U. A., and A. Minson.
1986.
The properties and sequence of glycoprotein H of herpes simplex type 1.
Virology
153:230-247[Medline].
|
| 12.
|
Gripon, P.,
C. Diot, and C. Guguen-Guillouzo.
1993.
Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effects of polyethylene glycol on adsorption and penetration.
Virology
192:534-540[Medline].
|
| 13.
|
Heineman, T.,
M. Gong,
J. Sample, and E. Kieff.
1988.
Identification of the Epstein-Barr virus gp85 gene.
J. Virol.
62:1101-1107[Abstract/Free Full Text].
|
| 14.
|
Hermann, A.,
M. J. Clague, and R. Blumenthal.
1993.
Enhancement of viral fusion by nonadsorbing polymers.
Biophysics
65:528-534.
|
| 15.
|
Heston, L.,
M. Rabson,
N. Brown, and G. Miller.
1982.
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma.
Nature (London)
295:160-163[Medline].
|
| 16.
|
Hoekstra, D.,
K. Klappe,
H. Hoff, and S. Nir.
1989.
Mechanism of fusion of Sendai virus: role of hydrophobic interactions and mobility constraints of viral glycoproteins. Effects of polyethylene glycol.
J. Biol. Chem.
264:6786-6792[Abstract/Free Full Text].
|
| 17.
|
Hoffman, G. J.,
S. G. Lazarowitz, and S. D. Hayward.
1980.
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
Proc. Natl. Acad. Sci. USA
77:2979-2983[Abstract/Free Full Text].
|
| 18.
|
Huber, M. T., and T. Compton.
1997.
Characterization of a novel third member of the human cytomegalovirus glycoprotein H-L complex.
J. Virol.
71:5391-5398[Abstract].
|
| 19.
|
Hutchinson, L.,
H. Browne,
V. Wargent,
N. Davis-Poynter,
S. Primorac,
K. Goldsmith,
A. C. Minson, and D. C. Johnson.
1992.
A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH.
J. Virol.
66:2240-2250[Abstract/Free Full Text].
|
| 20.
|
Hutt-Fletcher, L. M.,
N. Balachandran, and P. A. LeBlanc.
1986.
Modification of Epstein-Barr virus replication by tunicamycin.
J. Virol.
57:117-123[Abstract/Free Full Text].
|
| 21.
|
Kaye, J. F.,
U. A. Gompels, and A. C. Minson.
1992.
Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.
J. Gen. Virol.
73:2693-2698[Abstract/Free Full Text].
|
| 22.
|
Keller, P. M.,
A. J. Davison,
R. S. Lowe,
M. W. Riemen, and R. W. Ellis.
1987.
Identification and sequence of the gene encoding gpIII, a major glycoprotein of varicella-zoster virus.
Virology
157:526-523[Medline].
|
| 23.
|
Kurilla, M. G.,
T. Heineman,
L. C. Davenport,
E. Kieff, and L. M. Hutt-Fletcher.
1995.
A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame.
Virology
209:108-121[Medline].
|
| 24.
| Li, L., J. A. Nelson, and W. J. Britt.
Glycoprotein H-related complexes of human cytomegalovirus:
identification of a third protein in the gCIII complex. J. Virol.
71:3090-3097.
|
| 25.
|
Li, Q. X.,
M. K. Spriggs,
S. Kovats,
S. M. Turk,
M. R. Comeau,
B. Nepom, and L. M. Hutt-Fletcher.
1997.
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.
J. Virol.
71:4657-4662[Abstract].
|
| 26.
|
Li, Q. X.,
S. M. Turk, and L. M. Hutt-Fletcher.
1995.
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol.
69:3987-3994[Abstract].
|
| 27.
|
Liu, D. X.,
U. A. Gompels,
J. Nicholas, and C. Lelliott.
1993.
Identification and expression of the human herpesvirus 6 glycoprotein H and interaction with an accessory 40K glycoprotein.
J. Gen. Virol.
74:1847-1857[Abstract/Free Full Text].
|
| 28.
|
Liu, D. X.,
U. A. Gompels,
L. Foa-Tomasi, and G. Campadelli-Fiumi.
1993.
Human herpesvirus 6 glycoprotein H and L homologues are components of the gp100 complex and the gH external domain is the target for neutralizing monoclonal antibodies.
Virology
197:12-22[Medline].
|
| 29.
|
Miller, N., and L. M. Hutt-Fletcher.
1988.
A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.
J. Virol.
62:2366-2372[Abstract/Free Full Text].
|
| 30.
|
Nemerow, G. R., and N. R. Cooper.
1981.
Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement.
J. Immunol.
127:272-278[Abstract].
|
| 31.
|
Oba, D. E., and L. M. Hutt-Fletcher.
1988.
Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.
J. Virol.
62:1108-1114[Abstract/Free Full Text].
|
| 32.
|
Peeters, B.,
N. Dewind,
R. Broer,
A. Gielkins, and R. Moormann.
1992.
Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.
J. Virol.
66:3888-3892[Abstract/Free Full Text].
|
| 33.
|
Pulvertaft, R. J. V.
1964.
Cytology of Burkitt's tumor (African lymphoma).
Lancet
i:238-240.
|
| 34.
| Rasmussen, L., S. Resta, and T. C. Merigan.
1991. Human cytomegalovirus glycoprotein-receptor interactions.
Transplant. Proc. 23 Part 3, no. 3):60-63.
|
| 35.
|
Roop, C.,
L. Hutchinson, and D. C. Johnson.
1993.
A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.
J. Virol.
67:2285-2297[Abstract/Free Full Text].
|
| 36.
|
Shimizu, N.,
A. Tanabe-Tochikura,
Y. Kuroiwa, and K. Takada.
1994.
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
J. Virol.
68:6069-6073[Abstract/Free Full Text].
|
| 37.
|
Shimizu, N.,
H. Yoshiyama, and K. Takada.
1996.
Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.
J. Virol.
70:7260-7263[Abstract/Free Full Text].
|
| 38.
|
Spaete, R. R.,
K. Perot,
P. I. Scott,
J. A. Nelson,
M. F. Stinski, and C. Pachl.
1993.
Co-expression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface.
Virology
193:853-861[Medline].
|
| 39.
|
Spriggs, M. K.,
R. J. Armitage,
M. R. Comeau,
L. Strockbine,
T. Farrah,
B. MacDuff,
D. Ulrich,
M. R. Alderson,
J. Müllberg, and J. I. Cohen.
1996.
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR chain and inhibits antigen presentation.
J. Virol.
70:5557-5563[Abstract/Free Full Text].
|
| 40.
|
Strnad, B. C.,
T. Schuster,
R. Klein,
R. F. Hopkins III,
T. Witmer,
R. H. Neubauer, and H. Rabin.
1982.
Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.
J. Virol.
41:258-264[Abstract/Free Full Text].
|
| 41.
|
Takada, K.
1984.
Cross-linking of cell surface immunoglobulin induces Epstein-Barr virus in Burkitt lymphoma lines.
Int. J. Cancer
33:27-32[Medline].
|
| 42.
|
Takada, K.,
K. Horinouchi,
Y. Ono,
T. Aya,
T. Osato,
M. Takahashi, and S. Hayasaka.
1991.
An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.
Virus Genes
5:147-156[Medline].
|
| 43.
|
Telford, E. A.,
M. S. Watson,
H. C. Aird,
J. Perry, and A. J. Davison.
1995.
The DNA sequence of equine herpesvirus 2.
J. Mol. Biol.
249:520-528[Medline].
|
| 44.
|
Vik, D. P., and D. T. Fearon.
1985.
Neutrophils express a receptor for iC3b, C3dg and C3d that is distinct from CR1, CR2 and CR3.
J. Immunol.
134:2571-2579[Abstract].
|
| 45.
|
Yaswen, L. R.,
E. B. Stephens,
L. C. Davenport, and L. M. Hutt-Fletcher.
1993.
Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein.
Virology
195:387-396[Medline].
|
J Virol, January 1998, p. 158-163, Vol. 72, No. 1
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Plate, A. E., Smajlovic, J., Jardetzky, T. S., Longnecker, R.
(2009). Functional Analysis of Glycoprotein L (gL) from Rhesus Lymphocryptovirus in Epstein-Barr Virus-Mediated Cell Fusion Indicates a Direct Role of gL in gB-Induced Membrane Fusion. J. Virol.
83: 7678-7689
[Abstract]
[Full Text]
-
Reimer, J. J., Backovic, M., Deshpande, C. G., Jardetzky, T., Longnecker, R.
(2009). Analysis of Epstein-Barr Virus Glycoprotein B Functional Domains via Linker Insertion Mutagenesis. J. Virol.
83: 734-747
[Abstract]
[Full Text]
-
Veettil, M. V., Sadagopan, S., Sharma-Walia, N., Wang, F.-Z., Raghu, H., Varga, L., Chandran, B.
(2008). Kaposi's Sarcoma-Associated Herpesvirus Forms a Multimolecular Complex of Integrins ({alpha}V{beta}5, {alpha}V{beta}3, and {alpha}3{beta}1) and CD98-xCT during Infection of Human Dermal Microvascular Endothelial Cells, and CD98-xCT Is Essential for the Postentry Stage of Infection. J. Virol.
82: 12126-12144
[Abstract]
[Full Text]
-
Wang, D., Yu, Q.-C., Schroer, J., Murphy, E., Shenk, T.
(2007). Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc. Natl. Acad. Sci. USA
104: 20037-20042
[Abstract]
[Full Text]
-
Gillet, L., Stevenson, P. G.
(2007). Evidence for a Multiprotein Gamma-2 Herpesvirus Entry Complex. J. Virol.
81: 13082-13091
[Abstract]
[Full Text]
-
Chiu, Y.-F., Tung, C.-P., Lee, Y.-H., Wang, W.-H., Li, C., Hung, J.-Y., Wang, C.-Y., Kawaguchi, Y., Liu, S.-T.
(2007). A comprehensive library of mutations of Epstein Barr virus. J. Gen. Virol.
88: 2463-2472
[Abstract]
[Full Text]
-
Kirschner, A. N., Lowrey, A. S., Longnecker, R., Jardetzky, T. S.
(2007). Binding-Site Interactions between Epstein-Barr Virus Fusion Proteins gp42 and gH/gL Reveal a Peptide That Inhibits both Epithelial and B-Cell Membrane Fusion. J. Virol.
81: 9216-9229
[Abstract]
[Full Text]
-
Wu, L., Hutt-Fletcher, L. M.
(2007). Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses. J. Gen. Virol.
88: 2129-2136
[Abstract]
[Full Text]
-
Hutt-Fletcher, L. M.
(2007). Epstein-Barr Virus Entry. J. Virol.
81: 7825-7832
[Full Text]
-
Guerreiro-Cacais, A. O., Uzunel, M., Levitskaya, J., Levitsky, V.
(2007). Inhibition of Heavy Chain and {beta}2-Microglobulin Synthesis as a Mechanism of Major Histocompatibility Complex Class I Downregulation during Epstein-Barr Virus Replication. J. Virol.
81: 1390-1400
[Abstract]
[Full Text]
-
Gillet, L., May, J. S., Colaco, S., Stevenson, P. G.
(2007). Glycoprotein L Disruption Reveals Two Functional Forms of the Murine Gammaherpesvirus 68 Glycoprotein H. J. Virol.
81: 280-291
[Abstract]
[Full Text]
-
Jiang, R., Scott, R. S., Hutt-Fletcher, L. M.
(2006). Epstein-Barr Virus Shed in Saliva Is High in B-Cell-Tropic Glycoprotein gp42. J. Virol.
80: 7281-7283
[Abstract]
[Full Text]
-
Shannon-Lowe, C. D., Neuhierl, B., Baldwin, G., Rickinson, A. B., Delecluse, H.-J.
(2006). From the Cover: Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc. Natl. Acad. Sci. USA
103: 7065-7070
[Abstract]
[Full Text]
-
Wang, D., Shenk, T.
(2005). Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA
102: 18153-18158
[Abstract]
[Full Text]
-
Shannon-Lowe, C., Baldwin, G., Feederle, R., Bell, A., Rickinson, A., Delecluse, H.-J.
(2005). Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J. Gen. Virol.
86: 3009-3019
[Abstract]
[Full Text]
-
Omerovic, J., Lev, L., Longnecker, R.
(2005). The Amino Terminus of Epstein-Barr Virus Glycoprotein gH Is Important for Fusion with Epithelial and B Cells. J. Virol.
79: 12408-12415
[Abstract]
[Full Text]
-
Wu, L., Borza, C. M., Hutt-Fletcher, L. M.
(2005). Mutations of Epstein-Barr Virus gH That Are Differentially Able To Support Fusion with B Cells or Epithelial Cells. J. Virol.
79: 10923-10930
[Abstract]
[Full Text]
-
Ressing, M. E., van Leeuwen, D., Verreck, F. A. W., Keating, S., Gomez, R., Franken, K. L. M. C., Ottenhoff, T. H. M., Spriggs, M., Schumacher, T. N., Hutt-Fletcher, L. M., Rowe, M., Wiertz, E. J. H. J.
(2005). Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. J. Virol.
79: 841-852
[Abstract]
[Full Text]
-
McShane, M. P., Longnecker, R.
(2004). Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins. Proc. Natl. Acad. Sci. USA
101: 17474-17479
[Abstract]
[Full Text]
-
Guerreiro-Cacais, A. O., Li, L., Donati, D., Bejarano, M. T., Morgan, A., Masucci, M. G., Hutt-Fletcher, L., Levitsky, V.
(2004). Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J. Gen. Virol.
85: 2767-2778
[Abstract]
[Full Text]
-
Akkapaiboon, P., Mori, Y., Sadaoka, T., Yonemoto, S., Yamanishi, K.
(2004). Intracellular Processing of Human Herpesvirus 6 Glycoproteins Q1 and Q2 into Tetrameric Complexes Expressed on the Viral Envelope. J. Virol.
78: 7969-7983
[Abstract]
[Full Text]
-
Silva, A. L., Omerovic, J., Jardetzky, T. S., Longnecker, R.
(2004). Mutational Analyses of Epstein-Barr Virus Glycoprotein 42 Reveal Functional Domains Not Involved in Receptor Binding but Required for Membrane Fusion. J. Virol.
78: 5946-5956
[Abstract]
[Full Text]
-
Borza, C. M., Morgan, A. J., Turk, S. M., Hutt-Fletcher, L. M.
(2004). Use of gHgL for Attachment of Epstein-Barr Virus to Epithelial Cells Compromises Infection. J. Virol.
78: 5007-5014
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yonemoto, S., Koike, M., Takemoto, M., Sadaoka, T., Sasamoto, Y., Konishi, S., Uchiyama, Y., Yamanishi, K.
(2004). Discovery of a Second Form of Tripartite Complex Containing gH-gL of Human Herpesvirus 6 and Observations on CD46. J. Virol.
78: 4609-4616
[Abstract]
[Full Text]
-
Katzman, R. B., Longnecker, R.
(2003). Cholesterol-dependent infection of Burkitt's lymphoma cell lines by Epstein-Barr virus. J. Gen. Virol.
84: 2987-2992
[Abstract]
[Full Text]
-
Spear, P. G., Longnecker, R.
(2003). Herpesvirus Entry: an Update. J. Virol.
77: 10179-10185
[Full Text]
-
Ressing, M. E., van Leeuwen, D., Verreck, F. A. W., Gomez, R., Heemskerk, B., Toebes, M., Mullen, M. M., Jardetzky, T. S., Longnecker, R., Schilham, M. W., Ottenhoff, T. H. M., Neefjes, J., Schumacher, T. N., Hutt-Fletcher, L. M., Wiertz, E. J. H. J.
(2003). Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc. Natl. Acad. Sci. USA
100: 11583-11588
[Abstract]
[Full Text]
-
McShane, M. P., Mullen, M. M., Haan, K. M., Jardetzky, T. S., Longnecker, R.
(2003). Mutational Analysis of the HLA Class II Interaction with Epstein-Barr Virus Glycoprotein 42. J. Virol.
77: 7655-7662
[Abstract]
[Full Text]
-
Mori, Y., Yang, X., Akkapaiboon, P., Okuno, T., Yamanishi, K.
(2003). Human Herpesvirus 6 Variant A Glycoprotein H-Glycoprotein L-Glycoprotein Q Complex Associates with Human CD46. J. Virol.
77: 4992-4999
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yang, X., Yamanishi, K.
(2003). The Human Herpesvirus 6 U100 Gene Product Is the Third Component of the gH-gL Glycoprotein Complex on the Viral Envelope. J. Virol.
77: 2452-2458
[Abstract]
[Full Text]
-
Rasmussen, L., Geissler, A., Cowan, C., Chase, A., Winters, M.
(2002). The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates. J. Virol.
76: 10841-10848
[Abstract]
[Full Text]
-
Li, L., Liu, D., Hutt-Fletcher, L., Morgan, A., Masucci, M. G., Levitsky, V.
(2002). Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood
99: 3725-3734
[Abstract]
[Full Text]
-
Maruo, S., Yang, L., Takada, K.
(2001). Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol.
82: 2373-2383
[Abstract]
[Full Text]
-
Haan, K. M., Aiyar, A., Longnecker, R.
(2001). Establishment of Latent Epstein-Barr Virus Infection and Stable Episomal Maintenance in Murine B-Cell Lines. J. Virol.
75: 3016-3020
[Abstract]
[Full Text]
-
Lake, C. M., Hutt-Fletcher, L. M.
(2000). Epstein-Barr Virus That Lacks Glycoprotein gN Is Impaired in Assembly and Infection. J. Virol.
74: 11162-11172
[Abstract]
[Full Text]
-
Delecluse, H-J, Hammerschmidt, W
(2000). The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol. Pathol.
53: 270-279
[Abstract]
[Full Text]
-
Haan, K. M., Longnecker, R.
(2000). Coreceptor restriction within the HLA-DQ locus for Epstein-Barr virus infection. Proc. Natl. Acad. Sci. USA
10.1073/pnas.160171697v1
[Abstract]
[Full Text]
-
Molesworth, S. J., Lake, C. M., Borza, C. M., Turk, S. M., Hutt-Fletcher, L. M.
(2000). Epstein-Barr Virus gH Is Essential for Penetration of B Cells but Also Plays a Role in Attachment of Virus to Epithelial Cells. J. Virol.
74: 6324-6332
[Abstract]
[Full Text]
-
Haan, K. M., Kwok, W. W., Longnecker, R., Speck, P.
(2000). Epstein-Barr Virus Entry Utilizing HLA-DP or HLA-DQ as a Coreceptor. J. Virol.
74: 2451-2454
[Abstract]
[Full Text]
-
Huber, M. T., Compton, T.
(1998). The Human Cytomegalovirus UL74 Gene Encodes the Third Component of the Glycoprotein H-Glycoprotein L-Containing Envelope Complex. J. Virol.
72: 8191-8197
[Abstract]
[Full Text]
-
Borza, C. M., Hutt-Fletcher, L. M.
(1998). Epstein-Barr Virus Recombinant Lacking Expression of Glycoprotein gp150 Infects B Cells Normally but Is Enhanced for Infection of Epithelial Cells. J. Virol.
72: 7577-7582
[Abstract]
[Full Text]
-
Wang, X., Kenyon, W. J., Li, Q., Mullberg, J., Hutt-Fletcher, L. M.
(1998). Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL To Infect B Lymphocytes and Epithelial Cells. J. Virol.
72: 5552-5558
[Abstract]
[Full Text]
-
Lake, C. M., Molesworth, S. J., Hutt-Fletcher, L. M.
(1998). The Epstein-Barr Virus (EBV) gN Homolog BLRF1 Encodes a 15-Kilodalton Glycoprotein That Cannot Be Authentically Processed unless It Is Coexpressed with the EBV gM Homolog BBRF3. J. Virol.
72: 5559-5564
[Abstract]
[Full Text]
-
Haan, K. M., Longnecker, R.
(2000). Coreceptor restriction within the HLA-DQ locus for Epstein-Barr virus infection. Proc. Natl. Acad. Sci. USA
97: 9252-9257
[Abstract]
[Full Text]